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Abstract: Central Nervous System (CNS) involvement in multiple myeloma and/or multifocal
solitary plasmacytoma is rare. Although they are unique entities, multiple myeloma (MM) and
plasmacytoma represent a spectrum of plasma cell neoplastic diseases that can sometimes occur
concurrently. Plasmacytomas very often present as late-stage sequelae of MM. In this case report,
we report a 53-year-old female presenting with right abducens cranial nerve (CN) VI palsy as an
initial presentation secondary to lesion of the right clivus.
Keywords: multiple myeloma; plasmacytoma; abducens nerve palsy
1. Introduction
Central Nervous System (CNS) involvement in multiple myeloma (MM) is uncommon,
with an incidence of approximately 1% of all MM cases [1,2]. CNS involvement suggests the
presence of either advanced stage sequela of MM known as intracranial plasmacytomas (occurring
in up to 5% of patients) [3], or solitary plasmacytoma without evidence of systemic disease.
Intracranial plasmacytomas are more common in the base of the skull and theyoriginate from bone
or paranasal sinus soft tissue. Initial symptoms can manifest as isolated or multiple cranial nerve
(CN) deficits.
MM and intracranial plasmacytoma represent a spectrum of plasma cell neoplasm. MM typically
presents with bone pain secondary to lytic bone lesions, an increase in serum and/or urine monoclonal
protein concentration, hypercalcemia, anemia, persistent or recurrent infections, and/or acute renal
failure [4]. In contrast, solitary plasmacytomas are localized plasma cell tumors arising from soft tissue
(extramedullary plasmacytomas) or bones (solitary bone plasmacytomas) without evidence of systemic
MM disease [5,6]. While CNS involvement in MM is rare, it is sometimes the only clinical finding
initially present. It is important to recognize that plasmacytoma can be associated with MM and early
recognition will hasten intervention. Presented is a case of intracranial plasmacytoma associated with
MM in a patient who presented with abducens nerve (CN VI) palsy as the initial clinical manifestation
of the disease.
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2. Case Presentation
A 53-year-old female with a history of type 2 diabetes mellitus, hypertension, and hypothyroidism
presented with increasing diplopia and nausea for six days. The patient experienced an unintentional
weight loss of 10 pounds in the preceding two weeks. Physical exam revealed bony tenderness
localized to the ribs as well as a right CN VI palsy manifesting as impaired right eye abduction.
Remainder of the exam was unremarkable.
Hemogram with differential was remarkable for white count of 10,700 k/µL (3.7–10.3 k/µL),
with absolute neutrophil count of 7.5 k/µL (1.6–6.1 k/µL). Absolute lymphocyte count was within
normal limits (2.42 k/µL (1.6–6.1 k/µL)). Blood chemistry was remarkable for: serum Ca2+ of
15.8 mg/dL (8.9–10.2 mg/dL), ionized Ca2+ of 7.7 mg/dL (4.6–5.1 mg/dL), and glucose of 254 mg/dL
(90–120 mg/dL). Parathyroid hormone was <10 pg/mL (12–72 pg/mL) and parathyroid hormone
related peptide was 1.3 (normal). Urine analysis and urine protein electrophoresis was unremarkable
without evidence of Bence-Jones protein. The calculated protein gap between total protein (6.8 g/dL)
and serum globulin (2.8 g/dL) was 4.0 g/dL and the albumin/gamma globulin ratio was elevated at
2.4 (0.8–2.0).
Serum protein electrophoresis revealed faint monoclonal immunoglobulin.
Serum immune-quantification showed IgG 1150 mg/dL (720–1598 mg/dL), IgA 200 mg/dL
(75–400 mg/dL), and IgM 41 (35–225 mg/dL). Kappa light chain was 108.18 mg/L (3.30–19.4 mg/L),
lambda light chain 445.32 mg/L (5.71–26.30 mg/L), with a kappa/lambda free light chain ratio of 0.24
(0.26–1.65). Bone marrow biopsy results demonstrated hypercellular bone marrow involved by plasma
cell neoplasm (50–60% aberrant lambda restricted plasma cells). Fluorescence in situ hybridization
studies found evidence of CCND1/IGH gene fusion and gain of chromosome 1q. Flow cytometry of
bone marrow aspirate demonstrated a small population of aberrant lambda restricted plasma cells
positive for CD38, CD56, moderate CD45 and Lambda, and negative for CD19.
Computed tomography (CT) of the chest/abdomen revealed multiple osteolytic lesions in the
appendicular and axillary skeleton throughout the thoracolumbar vertebral bodies, and pelvic bones;
a healing non-displaced fifth anterior lateral rib fracture was present on the right. CT and magnetic
resonance imaging (MRI) of the head showed multiple bone lesions, with a well-defined lesion
measuring 12 × 15 mm within the right side of the clivus adjacent to Dorello’s canal (Figures 1 and 2).
Bone survey showed lytic lesions in the left proximal fibular diaphysis (Figure 3).
The patient’s hypercalcemia was treated with IV normal saline, calcitonin, and pamidronate.
Pain was controlled with acetaminophen and tramadol with oxycodone for breakthrough pain.
The patient was evaluated by the hematology-oncology service and received external beam
radiation therapy to the clivus, alleviating her CN VI palsy. Her disease was then managed with
cyclophosphamide, bortezomib, and dexamethasone (CyBorD) chemotherapy. With treatment her
symptoms resolved. Three months into therapy, her repeat laboratory testing demonstrated good
response to treatment. The lambda light chain had decreased to 13.1 mg/L (5.71–26.30 mg/L), with a
normal kappa/lambda free light chain ratio of 1.0 (0.26–1.65). Furthermore, a repeat bone marrow
biopsy was obtained, which showed no morphologic evidence of multiple myeloma.
J. Clin. Med. 2018, 7, 253 3 of 6
J. Clin. Med. 2018, 7, x FOR PEER REVIEW  3 of 6 
 
 
Figure 1. Axial CT head demonstrating lytic bone lesion (indicated by red triangle) within the right 
side of the clivus adjacent to Dorello’s canal likely accounting for the patient’s 6th nerve palsy.  
 
Figure 2. Axial T2 FS repeat (left) and T2 (right) demonstrating a discrete lesion (indicated by red 
triangle) in the same region as CT scan. Lesion is seen on the right clivus adjascent to Dorello’s canal 
and is likely responsible for CN 6 palsy. Lesion suspicious for myeloma and metastases. However, 
given the signal intensity and restricted diffusion lymphoma is also a possibility.  
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triangle) in the same region as CT scan. Lesion is seen on the right clivus adjascent to Dorello’s canal and
is likely responsible for CN 6 palsy. Lesion suspicious for myeloma and metastases. However, given
the signal intensity and restricted diffusion lymphoma is also a possibility.
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Figure 3. Bone survey demonstrated lytic lesions in the left proximal fibular diaphysis. 
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for about one percent of all cancers in the USA and is the second most common hematologic 
malignancy after lymphoma. In 2016, there were an estimated 30,300 new cases, 12,650 deaths, and 
an incidence of about 4–5 per 100,000 in the United States (US) [7]. Plasmacytoma constitutes less 
than 1% of intracranial tumors and can occur intramedullary or extramedullary. It can occur as a 
primary or secondary malignancy to widespread MM and can be classified into three groups. (1) 
plasmacytoma arising from the skull base; (2) plasmacytoma involving brain parenchyma +/− skull 
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vital in advanced MM disease as it is associated with increased morbidity and mortality when 
diagnosis is delayed.  
MM is believed to result from malignant transformation of post-germinal center plasma cells 
producing a monoclonal immunoglobulin, while plasmacytoma are tumors of plasma cells identical 
to that seen in MM [9]. Plasmacytomas that occur in the brain are termed intracranial plasmacytoma, 
and can arise from: (1) the clivus bone, which forms the junction between the basilar occipital and 
the sphenoid bone, (2) petrous part of the temporal bone, (3) or an extension of a plasmacytoma 
tumor arising from the submucosa of the nasopharyngeal region [3,8,10]. Due to the rarity of 
plasmacytomas, it is important to consider other differential diagnoses that include 
chondrosarcomas and meningiomas, and osteosarcomas and Ewing’s tumor for a plasmacytoma 
arising from the clivus and petrous bone, respectively [3,11].  
The symptoms of a plasmacytoma depend on the location and size of the tumor. Patients may 
present with headache, seizures, focal neurologic deficits, or cranial nerve palsies [11]. Although any 
cranial nerve can be affected, unilateral CN VI palsy is a common presentation [8]. This is due to the 
extended course taken by CN VI between the pons and the clivus to pierce the dura mater between 
the dura and skull. To achieve this, CN VI fibers pass via Dorello’s canal and bend at the petrous 
temporal bone, traveling into the superior orbital fissure to innervate the lateral rectus muscle of the 
eye. Patients with CN VI deficits will present with diplopia due to the inability to abduct the affected 
eye. Other nerves commonly affected include CN II and III [12].  
Figure 3. Bone survey demonstrated lytic lesions in the left proximal fibular diaphysis.
3. Discussion
MM and plasmacytoma are a spectrum of plasma cell neoplastic disease, with MM accounting for
about one percent of all cancers in the USA and is the second most common hematologic malignancy after
lymphoma. In 2016, there were an estimated 30,300 new cases, 12,650 deaths, and an incidence of about
4–5 per 100,000 in the United States (US) [7]. Plasmacytoma constitutes less than 1% of intracranial tumors
and can occur intramedullary or extramedullary. It can occur as a primary or secondary malignancy
to widespread MM and can be classified into three groups. (1) plasmacytoma arising from the skull
base; (2) plasmacytoma involving brain parenchyma +/− skull involvement termed “intracranial tumor
syndromes”; and, (3) plasmacytomas involving the orbit termed “intraorbital tumor syndrom s” [8].
Although pla macytoma is rare, early recognition is vital in advanced MM disease as it is associated with
increased morbidity an mortali y when diagnosis is delayed.
MM is believed to result from malignant transformation of post-germinal center plasma cells
producing a monoclonal immunoglobulin, while plasmacytoma are tumors of plasma cells identical
to that seen in MM [9]. Plasmacytomas that occur in the brain are termed intracranial plasmacytoma,
and can arise from: (1) the clivus bone, which forms the junction between the basilar occipital and the
sphenoid bone, (2) petrous part of the temporal bone, (3) or an extension of a plasmacytoma tumor
arising from the submucosa of the nasopharyngeal region [3,8,10]. Due to the rarity of plasmacytomas,
it is important to consider other differential diagnoses that include chondrosarcomas and meningiomas,
and osteosarco as and Ewing’s tum r for a plasmacytom arisi g from the clivus and petrous bone,
respectiv ly [3,11].
The symptoms of plasmacytom depend on the location and size of the tumor. Patients may
present with headache, seizures, focal neurologic deficits, or cranial nerve palsies [11]. Although any
cranial nerve can be affected, unilateral CN VI palsy is a common presentation [8]. This is due to the
extended course taken by CN VI between the pons and the clivus to pierce the dura mater between
the dura and skull. To achieve this, CN VI fibers pass via Dorello’s canal and bend at the petrous
temporal bone, traveling into the superior orbital fissure to innervate the lateral rectus muscle of the
eye. Patients with CN VI deficits will present with diplopia due to the inability to abduct the affected
eye. Other nerves commonly affected include CN II and III [12].
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As previously mentioned, a plasmacytoma can be solitary or secondary to MM. Diagnosis of a
solitary plasmacytoma depends on positive biopsy-proven clonal plasma cells solitary lesion without
any evidence of systemic MM disease. Diagnosis is confirmed with lytic homogenous, soft-tissue
density on CT or MRI. MRI is favored over CT for tumor imaging and it will show isointense focus [13].
Plasmacytomas can also arise in the context of MM [14].
Molecular characterization of MM can provide useful clinical information regarding prognosis and
therapy stratification. The presence of specific cytogenetic high-risk abnormalities, including t(4;14),
t(14;16), t(14;20), del(17p), and dup(1q) were previously identified to confer a poor prognosis [15–17].
On cytogenetic analysis, our patient was found to have CCND1/IGH gene fusion, which is commonly
known as t(11;14) fusion and dup(1q). It should be noted that t(11:14) is a neutral or favorable
prognostic factor in MM; however, in patients with light chain amyloidosis it confers a hazard ratio
for death of 2.5 [18]. Duplications of 1q are considered secondary genetic abnormalities in MM and
are typically associated with disease progression, high-risk disease, and shorter survival [17]. This is
likely secondary to the fact that duplications of 1q reflect an increase in the gene dosage of proliferative
genes, like CKS1B [16,17,19].
Clinically, it is difficult to ascertain whether a plasmacytoma is a clinical sequela of MM or if
the plasmacytoma progressed to MM. Nevertheless, both circumstances carry a worse prognosis
and should be aggressively treated. Treatment consists of localized radiotherapy for plasmacytoma
along with systemic chemotherapy for concurrent MM. The choice of chemotherapy regimen depends
on MM risk stratification; combination chemotherapy regimen, such as bortezomib, lenalidomide,
and low dose dexamethasone are often recommended initial agents for treatment [20].
4. Conclusions
CNS involvement in MM is rare. It commonly manifests as an intracranial plasmacytoma and
it typically indicates late stage MM with poor prognosis. The initial clinical presentation includes
diplopia, bone pain, and weight loss. Although a solitary plasmacytoma can manifest without MM
co-morbidity, it can progress to MM [11]. Thus, prompt recognition and treatment of the plasmacytoma
is warranted.
Our patient’s chief complaint was diplopia, with clinical findings of hypercalcemia and a clivus
bone lytic lesion being discovered on workup. Therefore, it is important to consider conducting an
MM workup in any patient presenting with diplopia and an accompanying lytic bone lesion found
on imaging.
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